Although DABK failed to increase tumor proliferation, our current study did find that BK treatment (B2R agonist) resulted in increased cell proliferation and the use of a B2R antagonist (FR173657) significantly decreased proliferation, further demonstrating that kinins do play a role in tumor proliferation. This evidence concerns the gene BDKRB2 and neoplasm.